Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...

The Paris AI Action Summit, under the banner of ethical AI innovation, appears disconnected from the realities of how ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

A confidential agreement has been made with manufacturer Vertex on how much the NHS will pay ... and can clump as they travel ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

Vertex Energy Inc (OTC:VTNRQ)., a petroleum refining company, disclosed its monthly operating reports for the periods ended September 30, October 31, and November 30 of 2024 as part of its ongoing ...

Vertex Inc is a provider of tax technology and ... While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.

From packable sleeping pads to ultracomfortable air beds, we tested and found the best camping mattresses and sleeping pads ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the drug could set the stage for the development of further compounds that target ...